Catherine Do - 26 Sep 2025 Form 4 Insider Report for Drugs Made In America Acquisition II Corp. (DMII)

Reporting relationship: Director
Issuer ticker: DMII
Reported as of: 26 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Oct 2025, 12:51:17 UTC
Prior SEC filing: 24 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Catherine Do

Key filing fact

Catherine Do filed Form 4 for Drugs Made In America Acquisition II Corp. (DMII) on 17 Oct 2025.

Key facts

This page summarizes Catherine Do's Form 4 filing for Drugs Made In America Acquisition II Corp. (DMII).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Oct 2025, 12:51.

Change

Previous filing in this sequence was filed on 24 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002040323 Primary reporting owner

Do Catherine

Relationship: Director
Address: C/O DRUGS MADE IN AMERICA ACQU. II CORP., 1 EAST BROWARD BOULEVARD, SUITE 700, FORT LAUDERDALE
Signature: /s/ Catherine Do
Signature date: 17 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DMII transaction

Ordinary shares

Other

Transaction value
Shares: +100,000
Change %
Price
Shares after: 100,000
Date: 26 Sep 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

As of the Transaction Date, the reporting person acquired 100,000 ordinary shares from Drugs Made In America Acquisition II LLC, the Issuer's sponsor, for no consideration.